Potential OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) user talking with friends.

Discover OPDIVO Qvantig, an immunotherapy treatment given by injection that's faster*

OPDIVO Qvantig is an alternative administrative option FDA approved to treat most cancer types approved for OPDIVO® (nivolumab).

Actor portrayals.

*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab) or in pediatric patients.

OPDIVO Qvantig is delivered in as little as 3-5 minutes

OPDIVO Qvantig is an immunotherapy treatment that is delivered differently than OPDIVO IV. Both work with the immune system in the same way, but OPDIVO Qvantig doesn’t need to be administered at an infusion center and may be given at a doctor’s office or a site closer to home. Ask your doctor if a subcutaneous injection may be right for you.

A physician preparing to administer a subcutaneous injection of OPDIVO® Qvantig™ to a patient’s abdomen.

Given as an intravenous infusion
directly into a vein using a needle or tube.

Takes 30 minutes
This refers only to the time it takes to receive treatment and does not account for all aspects of treatment. Actual time at the clinic may vary.

May require a port
A port is a small device that is surgically implanted and connected to a vein. When medication is administered, a needle connected to an IV tube is inserted into the port.

Given as an injection
by a healthcare professional under the skin in the stomach area (abdomen) or thigh area.

Takes 3-5 minutes
This refers only to the time it takes to give the injection and does not account for all aspects of treatment. Actual time at the clinic may vary.

No port needed
Since medication is injected under the skin and no access to a vein is required, a port is not necessary.

Alone or with other therapies, OPDIVO Qvantig is FDA approved to treat many types of cancer. Please see full list of eligible cancer types below.

OPDIVO Qvantig showed similar results and side effects to infusions of OPDIVO IV in a clinical trial

495 PEOPLE WITH PREVIOUSLY TREATED KIDNEY CANCER WERE STUDIED.

NO MAJOR DIFFERENCES WERE OBSERVED in the amount of medicine that went into the bloodstream between OPDIVO Qvantig and OPDIVO IV

  • OPDIVO Qvantig was studied in a clinical trial that showed similar results and side effects to infusions of OPDIVO. In the clinical trial, 495 people who had previously treated kidney cancer and had up to 2 therapies that didn't work were given either OPDIVO Qvantig injections or OPDIVO IV infusions. OPDIVO Qvantig injections and OPDIVO IV infusions were compared to check that the injection worked like the infusion. This was done by measuring the amount of medicine in the bloodstream after the medicines were given.

OPDIVO Qvantig injections are given by a healthcare provider in 3-5 minutes. This does not account for all aspects of treatment. Actual clinic time may vary.

What types of cancer is OPDIVO Qvantig FDA approved to treat?

See full indication list in the carousel at the top of the page.

OPDIVO Qvantig is approved alone or in combination with other cancer medication for adults with the following cancers.

Non-small cell lung cancer:

Early-stage non-small cell lung cancer (NSCLC) before surgery

Early-stage non-small cell lung cancer (NSCLC) before and after surgery

Advanced kidney cancer:

Previously untreated kidney cancer that has spread (advanced renal cell carcinoma) 

Previously untreated kidney cancer that has spread (advanced renal cell carcinoma) in combination with targeted therapy

Previously treated kidney cancer that has spread (advanced renal cell carcinoma)

Gastroesophageal cancer:

Previously untreated advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma that tests positive for PD-L1

Previously untreated advanced or metastatic esophageal squamous cell cancer (ESCC) that tests positive for PD-L1

Esophageal or gastroesophageal junction (GEJ) cancer that has been treated with  chemoradiation followed by surgery to help prevent it from coming back

Bladder cancer:

Bladder or urinary tract cancer after surgery

Advanced cancer in the bladder or urinary tract

Previously treated advanced bladder or urinary tract cancer

Head and neck squamous cell cancer:

Previously treated squamous cell cancer of the head and neck

Melanoma:

OPDIVO Qvantig is approved alone for adults and children 12 and older with the following cancers.

Melanoma that has spread or cannot be removed by surgery (advanced melanoma)

Stage 2B or stage 2C melanoma after it has been completely removed by surgery 

Stage 3 or stage 4 melanoma after it has been completely removed by surgery 

OPDIVO Qvantig is an FDA-approved alternative for most types of cancer in adults that can be treated with OPDIVO® (nivolumab)*†

Icon

Is OPDIVO Qvantig right for me?

Find out if OPDIVO Qvantig is right for you with answers to common questions people have about OPDIVO Qvantig.

This information is not a substitute for talking to your healthcare provider because they are the best source of information about your condition.

*Please note, treatment is delivered in 3-5 minutes. This refers only to the time it takes to give the injection and does not account for all aspects of treatment. Actual time at the clinic may vary.

OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab).

Download FAQ document 

"Cancer isn't me"

Rob, a husband and father of two, discusses his experience with OPDIVO® (nivolumab) + chemotherapy for advanced esophageal cancer.
image

Side effects tracker

Track your symptoms and other important information so that you can proactively manage potential side effects with your doctor

Two arms embracing to form a heart, signifying how the OPDIVO with You program may provide support for patients.

Medication guide

See which cancer types can be treated with OPDIVO Qvantig and possible side effects



1992-US-2500383 08/25